Neladalkib

DB21712InvestigationalSmall molecule

Neladalkib is a small molecule drug. The usage of the INN stem '-alkib' in the name indicates that Neladalkib is a ALK (anaplastic lymphoma kinase) inhibitor. Neladalkib is under investigation... Neladalkib is under investigation in clinical trial NCT06765109 (Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC).

Mechanism: Pharmacologically active on ALK tyrosine kinase receptor
Curator reviewed
Formula / weight: C₂₃H₂₂ClFN₆O · 452.92 g/mol (avg)
Also known as: an orally bioavailable ALK inhibitor (a macrocyclic compound containing nitrogen heterocycles)
Code names: NVL-655

Resolves to

Compound

UNIIJ32P26A6BCCAS2739866-40-9

Structure

InChIKeyFWZSCAQEBTVTOM-UHFFFAOYSA-NSMILESCCN1N=C(Cl)C2=C1C1=CN=C(N)C(O[C@H](C)C3=C(C=CC(F)=C3)C3=NN(C)C=C3C2)=C1

Targets

Q9UM73ALK

What you can answer from here — as of August 31, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Neladalkib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account